ADC Therapeutics SA Gross Profit 2019-2023 | ADCT
ADC Therapeutics SA gross profit from 2019 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
ADC Therapeutics SA Annual Gross Profit
(Millions of US $) |
| 2022 |
$205 |
| 2021 |
$33 |
| 2020 |
$ |
| 2019 |
$2 |
| 2018 |
$1 |
ADC Therapeutics SA Quarterly Gross Profit
(Millions of US $) |
| 2023-03-31 |
$18 |
| 2022-12-31 |
$69 |
| 2022-09-30 |
$75 |
| 2022-06-30 |
$15 |
| 2022-03-31 |
$46 |
| 2021-12-31 |
$16 |
| 2021-09-30 |
$13 |
| 2021-06-30 |
$4 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
$2 |
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.191B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
